TY - JOUR
T1 - Aspirin in the Treatment and Prevention of Migraine Headaches
T2 - Possible Additional Clinical Options for Primary Healthcare Providers
AU - Biglione, Bianca
AU - Gitin, Alexander
AU - Gorelick, Philip B.
AU - Hennekens, Charles
N1 - Funding Information:
Funding: None. Conflict of Interest: PBG discloses that he or his employer Thorek Memorial Hospital receives honoraria for his role as a member of adjudication committees for Allergan, AstraZeneca, Bristol-Myers Squibb-Sanofi, Allergan, TEVA, and Union Chimique Belge; steering committees for the ARRIVE trial funded by Bayer, and another funded by Brainsgate; and data and safety monitoring boards for Amgen, Novartis, and Sanofi. CH discloses that he serves as an independent scientist in an advisory role to investigators and sponsors as chair or member of data and safety monitoring boards for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, Regeneron, and the Wellcome Foundation, to the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; and has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/4
Y1 - 2020/4
N2 - Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers. In the treatment of acute migraine and the prevention of recurrent attacks, there are prescription drugs of proven benefit. However, for those without health insurance or high co-pays, these drugs may be neither available nor affordable and, for all patients, they may be either poorly tolerated or contraindicated. The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 mg, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin, in doses from 81 to 325 mg, may be an effective and safe treatment option for the prevention of recurrent migraine headaches. The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.
AB - Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers. In the treatment of acute migraine and the prevention of recurrent attacks, there are prescription drugs of proven benefit. However, for those without health insurance or high co-pays, these drugs may be neither available nor affordable and, for all patients, they may be either poorly tolerated or contraindicated. The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 mg, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin, in doses from 81 to 325 mg, may be an effective and safe treatment option for the prevention of recurrent migraine headaches. The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.
KW - Aspirin
KW - Migraine
KW - Prevention
KW - Primary healthcare providers
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85076555787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076555787&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2019.10.023
DO - 10.1016/j.amjmed.2019.10.023
M3 - Review article
C2 - 31712099
AN - SCOPUS:85076555787
SN - 0002-9343
VL - 133
SP - 412
EP - 416
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 4
ER -